Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2016


#862935

68pages

Global Markets Direct

$ 2000

In Stock

Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenocortical Carcinoma Pipeline Review, H2 2016, provides an overview of the Adrenocortical Carcinoma (Oncology) pipeline landscape.

Adrenal cortex cancer (ACC) is a rare disease. It is caused by a cancerous growth in the adrenal cortex, which is the outer layer of the adrenal glands. Predisposing factors include female, hereditary disease that affects the adrenal glands, age and smoking. Symptoms include high blood sugar and pressure, muscle weakness in the legs, excessive weight gain in chest and abdomen, early signs of puberty in children, increased facial and body hair, particularly in females and deepened voice in females.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adrenocortical Carcinoma Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Adrenocortical Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Adrenocortical Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Discovery stages are 5 and 1 respectively for Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively for Adrenocortical Carcinoma.

Adrenocortical Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenocortical Carcinoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Adrenocortical Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Adrenocortical Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Adrenocortical Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Adrenocortical Carcinoma (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Adrenocortical Carcinoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Adrenocortical Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Adrenocortical Carcinoma (Adrenal Cortex Cancer) Overview 6
Therapeutics Development 7
Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Overview 7
Pipeline Products for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis 8
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics under Development by Companies 9
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics under Investigation by Universities/Institutes 10
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Products under Development by Companies 13
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Products under Investigation by Universities/Institutes 14
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Companies Involved in Therapeutics Development 15
ArQule, Inc. 15
EnGeneIC Ltd 16
Exelixis, Inc. 17
Merck KGaA 18
Millendo Therapeutics, Inc. 19
Orphagen Pharmaceuticals, Inc. 20
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Target 22
Assessment by Mechanism of Action 24
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
ARQ-087 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
ATR-101 - Drug Profile 32
Product Description 32
Mechanism Of Action 32
R&D Progress 32
avelumab - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
cabozantinib s-malate - Drug Profile 40
Product Description 40
Mechanism Of Action 40
R&D Progress 40
Monoclonal Antibody Conjugate to Target B7-H3 for Oncology - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease - Drug Profile 59
Product Description 59
Mechanism Of Action 59
R&D Progress 59
TargomiRs - Drug Profile 60
Product Description 60
Mechanism Of Action 60
R&D Progress 60
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects 62
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products 63
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Product Development Milestones 64
Featured News & Press Releases 64
Mar 18, 2016: Millendo Therapeutics Announces Publication of Preclinical Data for ATR-101 and Data Presentations at ENDO 2016 64
Mar 03, 2015: Atterocor Announces Data Presentations at ENDO 2015 64
Dec 11, 2014: Atterocor Expands Phase 1 Trial of ATR-101 to Additional Leading Adrenal Cancer Centers 65
Oct 15, 2013: Atterocor Announces Initiation of Phase 1 Clinical Trial of ATR-101 in Adrenocortical Carcinoma 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 67
Disclaimer 68

List of Tables
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2016 7
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 11
Comparative Analysis by Early Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by ArQule, Inc., H2 2016 15
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by EnGeneIC Ltd, H2 2016 16
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Exelixis, Inc., H2 2016 17
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Merck KGaA, H2 2016 18
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Millendo Therapeutics, Inc., H2 2016 19
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2016 20
Assessment by Monotherapy Products, H2 2016 21
Number of Products by Stage and Target, H2 2016 23
Number of Products by Stage and Mechanism of Action, H2 2016 25
Number of Products by Stage and Route of Administration, H2 2016 27
Number of Products by Stage and Molecule Type, H2 2016 29
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Dormant Projects, H2 2016 62
Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Discontinued Products, H2 2016 63

List of Figures
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer), H2 2016 7
Number of Products under Development for Adrenocortical Carcinoma (Adrenal Cortex Cancer) - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Comparative Analysis by Clinical Stage Development, H2 2016 11
Assessment by Monotherapy Products, H2 2016 21
Number of Products by Top 10 Targets, H2 2016 22
Number of Products by Stage and Top 10 Targets, H2 2016 22
Number of Products by Top 10 Mechanism of Actions, H2 2016 24
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 24
Number of Products by Routes of Administration, H2 2016 26
Number of Products by Stage and Routes of Administration, H2 2016 26
Number of Products by Molecule Types, H2 2016 28
Number of Products by Stage and Molecule Types, H2 2016 28